MRNY

MRNY aims to generate monthly income while providing exposure to the price returns of the Moderna stock (MRNA), subject to a cap on potential investment gains. The fund utilizes a synthetic covered call strategy via standardized exchange-traded and FLEX options, which consists of three elements: i) synthetic long exposure, ii) covered call writing, and iii) US Treasurys. The synthetic long exposure seeks to replicate the price movements of MRNA by purchasing and selling "at-the-money" call and put options that generally have six-month to one-year terms. To generate income, the fund writes call options with an expiration of one month or less and a strike price of approx. 5%-15% above MRNA's current share price. This limits the fund's participation in potential gains if MRNA shares increase in value. The short put positions fully expose investors to the downside of the stock. Lastly, the fund holds cash and short-term Treasury securities as collateral. Note: the fund does not invest directly in Moderna stocks. Thus, investors are not entitled to any MRNA dividends.